20:33 , Dec 6, 2018 |  BC Innovations  |  Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
22:55 , Jun 22, 2018 |  BC Extra  |  Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

A Harvard Medical School team led by immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus (HERV) transcription to activate an immune response that could help treat...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
18:50 , Jul 21, 2017 |  BC Week In Review  |  Company News

Roche ends cancer deal with Oryzon

Roche (SIX:ROG; OTCQX:RHHBY) terminated a 2014 deal with Oryzon Genomics S.A. (Madrid:ORY) granting the pharma rights to cancer candidate ORY-1001 . Oryzon said Roche's decision was part of a portfolio reprioritization. Roche is responsible for...
23:40 , Jul 20, 2017 |  BC Extra  |  Company News

Roche ends cancer deal with Oryzon

Oryzon Genomics S.A. (Madrid:ORY) fell €0.80 (27%) to €2.11 on Thursday after Roche (SIX:ROG;OTCQX:RHHBY) terminated a 2014 deal granting the pharma rights to cancer candidate ORY-1001 . Oryzon said Roche's decision was part of a...
18:11 , Jun 16, 2017 |  BioCentury  |  Product Development

Everywhere IDO

Incyte Corp. and partner Merck & Co. Inc. now have reported the data that led them to plan Phase III trials that combine their molecules in five cancer indications. For Incyte, the next step is...
23:20 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

IMG-7289: Ph I/II started

Imago began an open-label, Australian Phase I/II trial to evaluate oral IMG-7289 with and without tretinoin in 30 patients. The dose-escalation Phase I portion will identify the selected dose of IMG-7289 for the dose-expansion Phase...